AR064713A1 - FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS - Google Patents

FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS

Info

Publication number
AR064713A1
AR064713A1 ARP070105988A ARP070105988A AR064713A1 AR 064713 A1 AR064713 A1 AR 064713A1 AR P070105988 A ARP070105988 A AR P070105988A AR P070105988 A ARP070105988 A AR P070105988A AR 064713 A1 AR064713 A1 AR 064713A1
Authority
AR
Argentina
Prior art keywords
understand
fusion protein
transglutaminases
compositions
methods
Prior art date
Application number
ARP070105988A
Other languages
Spanish (es)
Inventor
P Maffia
D Chiappetta
H Chuluyan
R Reiteri
S Gomez
V Garcia
M Costa
N Amiano
D Guerrieri
N Tateosian
Original Assignee
Consejo Nac Invest Cient Tec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec filed Critical Consejo Nac Invest Cient Tec
Priority to ARP070105988A priority Critical patent/AR064713A1/en
Priority to PCT/IB2008/055409 priority patent/WO2009083880A1/en
Publication of AR064713A1 publication Critical patent/AR064713A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)

Abstract

Proteína de fusion que se une a transglutaminasas, composiciones que la comprenden, micro-esferas que la comprenden, usos y métodos. La proteína de fusion podría comprender un dominio que se une a transglutaminasas, por ejemplo el dominio cementoín y un inhibidor de serina proteasas, poe ejemplo el inhibidor secretorio de proteasas leucocitarias (SLPI). Las proteínas de fusion son utiles para elaborar medicamentos para el tratamiento de: por ejemplo, enfermedades autoinmunes, procesos inflamatorios, cáncer, infecciones y la cicatrizacion de heridas.Fusion protein that binds to transglutamines, compositions that comprise it, microspheres that comprise it, uses and methods. The fusion protein could comprise a domain that binds to transglutaminases, for example the cement domain and a serine protease inhibitor, for example the secretory leukocyte protease inhibitor (SLPI). Fusion proteins are useful for developing medications for the treatment of: for example, autoimmune diseases, inflammatory processes, cancer, infections and wound healing.

ARP070105988A 2007-12-28 2007-12-28 FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS AR064713A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP070105988A AR064713A1 (en) 2007-12-28 2007-12-28 FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS
PCT/IB2008/055409 WO2009083880A1 (en) 2007-12-28 2008-12-18 Transglutaminases binding fusion protein, compositions comprising thereof, micro-spheres comprising thereof uses and methods

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070105988A AR064713A1 (en) 2007-12-28 2007-12-28 FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS

Publications (1)

Publication Number Publication Date
AR064713A1 true AR064713A1 (en) 2009-04-22

Family

ID=40473434

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105988A AR064713A1 (en) 2007-12-28 2007-12-28 FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS

Country Status (2)

Country Link
AR (1) AR064713A1 (en)
WO (1) WO2009083880A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
PT2726092T (en) 2011-06-28 2019-10-08 Lp Inhibrx Serpin fusion polypeptides and methods of use thereof
US8986688B2 (en) * 2011-06-28 2015-03-24 Inhibrx, Llc WAP domain fusion polypeptides and methods of use thereof
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110152496B (en) * 2018-01-30 2021-10-15 广州达济医学科技有限公司 Leukocyte filtering membrane and preparation method thereof
WO2023122120A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Compositionsand methods for wound healing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins

Also Published As

Publication number Publication date
WO2009083880A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
CY1124802T1 (en) SCLEROSTEIN BINDING FACTORS
CL2011000010A1 (en) Monoclonal anti-beta-amyloid peptide antibody; polynucleotide that encodes it; hybridoma; Method of production; composition comprising it; use to treat diseases related to amyloid proteins; method of diagnosing them; and kit that includes it.
EA201490265A1 (en) BLUTON TYROSINKINASE INHIBITORS
CL2019003093A1 (en) Anti-trem2 antibodies and methods of using them.
EA201270553A1 (en) BLUTON TYROSINKINASE INHIBITORS
EA200901313A1 (en) BLUTON TYROSINKINASE INHIBITORS
CY1113199T1 (en) STABILIZED GLUCOSEREMPRODUCTION COMPOSITIONS
AR064713A1 (en) FUSION PROTEIN THAT JOINS TRANSGLUTAMINASES, COMPOSITIONS THAT UNDERSTAND IT, MICRO-SPHERES THAT UNDERSTAND IT, USES AND METHODS
AR061246A1 (en) ANTI-DILL4 ANTIBODIES AND METHODS THAT USE THEM
NO20071740L (en) Humanized anti-beta7 antagonists and their applications
ECSP15005376A (en) 2,3-BENZODIAZEPINES
EA201201533A1 (en) PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
BR112013017080A8 (en) ANTIBODY OR FUNCTIONAL FRAGMENT THEREOF WHICH BINDS THE ACTIVE FORM OF HUMAN PLASMA KALLICREIN, PHARMACEUTICAL COMPOSITION AND METHOD OF DETECTION OF PLASMA KALLICREIN IN A PATIENT
CO6710903A2 (en) An antibody that specifically recognizes and binds with a phospho-epitope in the mammalian tau protein or in one of its fragments and a composition comprising the same
CR20110544A (en) SPECIFIC ANTAGONIST ANTIBODY FOR THE ALFA-4-BETA-7 HETERODYMER
CR10237A (en) ANTIBODIES AGAINST HUMAN IL-22 AND USES FOR THE SAME
ATE554105T1 (en) ALTERED ANTIBODIES
CL2008002952A1 (en) Antigen-binding protein that binds human interleukin-23 (yl-23); pharmaceutical composition comprising it; and its use to treat immune mediated inflammations
BR112014028785A2 (en) st2 antigen binding proteins
CO6351750A2 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES THAT GO TO THE COMPLEMENT PROTEIN C5
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
CL2007001665A1 (en) Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.
CL2011002756A1 (en) Antibody that binds to human or cynomolgus complement protein c3b; pharmaceutical composition, nucleic acid, vector and host cell comprising said antibody; use to treat age-related macular degeneration.
CL2008003784A1 (en) Humanized anti-hepatitis c virus e2 protein antibody or binding fragment; nucleic acid that encodes it; vector and host cell comprising said nucleic acid; method of producing the antibody; pharmaceutical composition comprising the antibody
CL2008001675A1 (en) Simple variable domain (dab) of immunoglobulin anti-vascular endothelial growth factor (vegf); nucleic acid encoding it; vector and host cell; method of production; vegf antogonist comprising the dab; composition comprising antogonist; and use of the antagonist to prepare a medicament.

Legal Events

Date Code Title Description
FC Refusal